Zai Lab (ZLAB) Competitors $35.52 +0.33 (+0.94%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZLAB vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Zai Lab (NASDAQ:ZLAB) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership. Which has more volatility and risk, ZLAB or ITCI? Zai Lab has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Which has stronger valuation & earnings, ZLAB or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Zai Lab. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M9.88-$257.10M-$2.49-14.25Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do insiders and institutionals have more ownership in ZLAB or ITCI? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 5.0% of Zai Lab shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend ZLAB or ITCI? Zai Lab presently has a consensus price target of $54.28, indicating a potential upside of 52.95%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Zai Lab's stronger consensus rating and higher probable upside, equities research analysts clearly believe Zai Lab is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is ZLAB or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Zai Lab's net margin of -60.26%. Intra-Cellular Therapies' return on equity of -9.93% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-60.26% -33.35% -23.28% Intra-Cellular Therapies -14.07%-9.93%-8.38% Does the media refer more to ZLAB or ITCI? In the previous week, Zai Lab had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 4 mentions for Zai Lab and 1 mentions for Intra-Cellular Therapies. Zai Lab's average media sentiment score of 1.26 beat Intra-Cellular Therapies' score of 0.29 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryZai Lab and Intra-Cellular Therapies tied by winning 8 of the 16 factors compared between the two stocks. Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.94B$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-14.2520.2728.5819.56Price / Sales9.88298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book4.627.668.165.58Net Income-$257.10M-$55.11M$3.24B$257.82M7 Day Performance-0.49%0.03%-0.64%-0.39%1 Month Performance-12.66%7.47%4.93%7.80%1 Year Performance90.98%-3.28%26.04%12.95% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab3.2938 of 5 stars$35.52+0.9%$54.28+52.8%+95.5%$3.93B$398.99M-14.221,869Positive NewsITCIIntra-Cellular Therapies0.9091 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9035 of 5 stars$20.52+1.1%$37.60+83.2%-20.3%$13.02B$3.12B11.662,682Positive NewsAnalyst RevisionRDYDr. Reddy's Laboratories2.7714 of 5 stars$15.08flat$16.95+12.4%-9.5%$12.59B$325.54B22.8527,811Positive NewsMRNAModerna4.3521 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.79B$3.24B-3.425,800Analyst ForecastAnalyst RevisionRGCRegencell Bioscience0.3382 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Positive NewsGap UpHigh Trading VolumeVTRSViatris2.9 of 5 stars$9.20-1.3%$10.40+13.0%-18.8%$10.94B$14.74B-2.9032,000News CoverageQGENQIAGEN3.6818 of 5 stars$47.49-1.8%$49.40+4.0%+16.7%$10.75B$1.98B119.075,765Positive NewsASNDAscendis Pharma A/S3.7164 of 5 stars$175.98+1.0%$220.67+25.4%+27.5%$10.65B$393.54M-28.021,017Positive NewsBBIOBridgeBio Pharma4.631 of 5 stars$43.50-1.1%$58.85+35.3%+68.7%$8.35B$221.90M-12.32400Analyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0895 of 5 stars$128.40+0.0%$128.06-0.3%+8.2%$8.29B$508.82M-51.98640Positive News Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Regencell Bioscience Alternatives Viatris Alternatives QIAGEN Alternatives Ascendis Pharma A/S Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZLAB Stock Alerts